Jpmorgan Chase & CO Sensei Biotherapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Sensei Biotherapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 702 shares of SNSE stock, worth $5,307. This represents 0.0% of its overall portfolio holdings.

Number of Shares

702

Previous 705 0.43%

Holding current value

$5,307

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$0.39 - $0.55 $1 - $1	-3 Reduced 0.43%	702 $0
Q4 2024 Feb 12, 2025	SELL	$0.41 - $0.78 $0 - $1	-2 Reduced 0.28%	705 $0
Q3 2024 Dec 26, 2024	SELL	$0.48 - $0.72 $19 - $29	-41 Reduced 5.48%	707 $0
Q3 2024 Nov 08, 2024	SELL	$0.48 - $0.72 $19 - $29	-41 Reduced 5.48%	707 $0
Q2 2024 Dec 26, 2024	BUY	$0.59 - $1.84 $24 - $75	41 Added 5.8%	748 $0
Q2 2024 Aug 12, 2024	BUY	$0.59 - $1.84 $47 - $147	80 Added 11.98%	748 $0
Q1 2024 Dec 26, 2024	SELL	$0.73 - $1.17 $28 - $45	-39 Reduced 5.52%	668 $0
Q4 2023 Dec 26, 2024	SELL	$0.53 - $0.82 $20 - $31	-39 Reduced 5.52%	668 $0
Q4 2022 Feb 13, 2023	SELL	$1.33 - $1.74 $1,389 - $1,818	-1,045 Reduced 61.0%	668 $1,000
Q3 2022 Nov 14, 2022	BUY	$1.55 - $2.24 $638 - $922	412 Added 31.67%	1,713 $3,000
Q2 2022 Aug 11, 2022	SELL	$1.49 - $2.3 $231,045 - $356,647	-155,064 Reduced 99.17%	1,301 $3,000
Q1 2022 May 11, 2022	SELL	$2.22 - $6.07 $7,576 - $20,716	-3,413 Reduced 2.14%	156,365 $361,000
Q4 2021 Feb 10, 2022	SELL	$4.85 - $10.48 $46,375 - $100,209	-9,562 Reduced 5.65%	159,778 $926,000
Q3 2021 Nov 12, 2021	BUY	$6.89 - $11.99 $1.17 Million - $2.03 Million	169,340 New	169,340 $1.78 Million

Others Institutions Holding SNSE

# of Institutions

Shares Held

43.3K

Call Options Held

Put Options Held

View Full List

About Sensei Biotherapeutics, Inc.

Ticker SNSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,720,300
Market Cap $232M
Description
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune res...

More about SNSE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Sensei Biotherapeutics, Inc. Transaction History